126 related articles for article (PubMed ID: 24264251)
1. The expected outcome of the Trypanosoma cruzi proteomic map: a review of its potential biological applications for drug target discovery.
Menna-Barreto RF; Perales J
Subcell Biochem; 2014; 74():305-22. PubMed ID: 24264251
[TBL] [Abstract][Full Text] [Related]
2. Proteomic and bioinformatic analysis of Trypanosoma cruzi chemotherapy and potential drug targets: new pieces for an old puzzle.
Sadok Menna-Barreto RF; Belloze KT; Perales J; Silva FP
Curr Drug Targets; 2014 Mar; 15(3):255-71. PubMed ID: 24041335
[TBL] [Abstract][Full Text] [Related]
3. Reevaluating the Trypanosoma cruzi proteomic map: The shotgun description of bloodstream trypomastigotes.
Brunoro GV; Caminha MA; Ferreira AT; Leprevost Fda V; Carvalho PC; Perales J; Valente RH; Menna-Barreto RF
J Proteomics; 2015 Feb; 115():58-65. PubMed ID: 25534883
[TBL] [Abstract][Full Text] [Related]
4. Trypanosoma cruzi chemical proteomics using immobilized benznidazole.
Trochine A; Alvarez G; Corre S; Faral-Tello P; Durán R; Batthyany CI; Cerecetto H; González M; Robello C
Exp Parasitol; 2014 May; 140():33-8. PubMed ID: 24632192
[TBL] [Abstract][Full Text] [Related]
5. Genome-scale metabolic models highlight stage-specific differences in essential metabolic pathways in Trypanosoma cruzi.
Shiratsubaki IS; Fang X; Souza ROO; Palsson BO; Silber AM; Siqueira-Neto JL
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008728. PubMed ID: 33021977
[TBL] [Abstract][Full Text] [Related]
6. The challenge of Chagas' disease: has the human pathogen, Trypanosoma cruzi, learned how to modulate signaling events to subvert host cells?
Lima FM; Oliveira P; Mortara RA; Silveira JF; Bahia D
N Biotechnol; 2010 Dec; 27(6):837-43. PubMed ID: 20172059
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics, lipidomics and proteomics profiling of myoblasts infected with Trypanosoma cruzi after treatment with different drugs against Chagas disease.
Hennig K; Abi-Ghanem J; Bunescu A; Meniche X; Biliaut E; Ouattara AD; Lewis MD; Kelly JM; Braillard S; Courtemanche G; Chatelain E; Béquet F
Metabolomics; 2019 Aug; 15(9):117. PubMed ID: 31440849
[TBL] [Abstract][Full Text] [Related]
8. Proteomic map of Trypanosoma cruzi CL Brener: the reference strain of the genome project.
Sodré CL; Chapeaurouge AD; Kalume DE; de Mendonça Lima L; Perales J; Fernandes O
Arch Microbiol; 2009 Feb; 191(2):177-84. PubMed ID: 19002435
[TBL] [Abstract][Full Text] [Related]
9. Cell surface proteome analysis of human-hosted Trypanosoma cruzi life stages.
Queiroz RM; Charneau S; Bastos IM; Santana JM; Sousa MV; Roepstorff P; Ricart CA
J Proteome Res; 2014 Aug; 13(8):3530-41. PubMed ID: 24978697
[TBL] [Abstract][Full Text] [Related]
10. A proteomic analysis of the mechanism of action of naphthoimidazoles in Trypanosoma cruzi epimastigotes in vitro.
Menna-Barreto RF; Beghini DG; Ferreira AT; Pinto AV; De Castro SL; Perales J
J Proteomics; 2010 Nov; 73(12):2306-15. PubMed ID: 20621210
[TBL] [Abstract][Full Text] [Related]
11. Quantitative proteomics of Trypanosoma cruzi during metacyclogenesis.
de Godoy LM; Marchini FK; Pavoni DP; Rampazzo Rde C; Probst CM; Goldenberg S; Krieger MA
Proteomics; 2012 Aug; 12(17):2694-703. PubMed ID: 22761176
[TBL] [Abstract][Full Text] [Related]
12. Trypanocidal activity and selectivity in vitro of aromatic amidine compounds upon bloodstream and intracellular forms of Trypanosoma cruzi.
De Souza EM; da Silva PB; Nefertiti AS; Ismail MA; Arafa RK; Tao B; Nixon-Smith CK; Boykin DW; Soeiro MN
Exp Parasitol; 2011 Feb; 127(2):429-35. PubMed ID: 20971106
[TBL] [Abstract][Full Text] [Related]
13. Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi.
Aguilera-Venegas B; Olea-Azar C; Arán VJ; Speisky H
Future Med Chem; 2013 Oct; 5(15):1843-59. PubMed ID: 24144415
[TBL] [Abstract][Full Text] [Related]
14. [Trypanosoma cruzi: transport of essential metabolites acquired from the host].
Pereira CA; Carrillo C; Miranda MR; Bouvier LA; Cánepa GE
Medicina (B Aires); 2008; 68(5):398-404. PubMed ID: 18977714
[TBL] [Abstract][Full Text] [Related]
15. Activity of "reversed" diamidines against Trypanosoma cruzi "in vitro".
Silva CF; Batista MM; Mota RA; de Souza EM; Stephens CE; Som P; Boykin DW; Soeiro Mde N
Biochem Pharmacol; 2007 Jun; 73(12):1939-46. PubMed ID: 17462605
[TBL] [Abstract][Full Text] [Related]
16. Naftifine-analogues as anti-Trypanosoma cruzi agents.
Gerpe A; Boiani L; Hernández P; Sortino M; Zacchino S; González M; Cerecetto H
Eur J Med Chem; 2010 Jun; 45(6):2154-64. PubMed ID: 20163894
[TBL] [Abstract][Full Text] [Related]
17. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
19. Proximity-Dependent Biotinylation and Identification of Flagellar Proteins in Trypanosoma cruzi.
Won MM; Baublis A; Burleigh BA
mSphere; 2023 Jun; 8(3):e0008823. PubMed ID: 37017578
[TBL] [Abstract][Full Text] [Related]
20. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole.
Benaim G; Sanders JM; Garcia-Marchán Y; Colina C; Lira R; Caldera AR; Payares G; Sanoja C; Burgos JM; Leon-Rossell A; Concepcion JL; Schijman AG; Levin M; Oldfield E; Urbina JA
J Med Chem; 2006 Feb; 49(3):892-9. PubMed ID: 16451055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
